ClearMed
BriefingsDrug & Biomarker IndexSaved (0)
All Oncology BriefingsCancer Discovery
OncologyPhase III2 min read

First mRNA Cancer Vaccine Succeeds in Phase III Trial

Adding the mRNA-based individualized tumor-specific protein flag (neoantigen) vaccine intismeran autogene to the PD-1 inhibitor pembrolizumab following surgery for melanoma reduced the risk of disease recurrence or death substantially, according to the results of the Phase III INTerpath-0001 trial.

Published in Cancer DiscoveryPhase III clinical trial
5/5 Gold Standard
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

Source

Clinical Outcome

42%

The data were presented at the ESMO Congress 2026, held October 23-27, in Madrid, Spain.

What Changes?

Oncology · Phase III

Current Standard

Conventional oncology practice relies on standard-of-care monitoring and existing regimens prior to this Phase III clinical trial.

New Finding

Published in Cancer discovery, these peer-reviewed oncology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.

3 Key Takeaways

Plain English Summary
  1. 01Core Finding

    Delivered via first Cancer Vaccine, this Phase III approach targets .

  2. 02Study Evidence

    Tested in a Phase III multicenter trial · Phase III clinical trial at the Phase III stage.

  3. 03Practical Meaning

    Large Phase III clinical evidence — long-term durability and rare subgroup effects remain under study.

What This Means for You

Published in Cancer discovery, these peer-reviewed oncology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.

The Discovery

Adding the -based individualized tumor-specific protein flag () vaccine intismeran autogene to the PD-1 inhibitor pembrolizumab following surgery for melanoma reduced the risk of disease recurrence or death substantially, according to the results of the Phase III INTerpath-0001 trial. The data were presented at the ESMO Congress 2026, held October 23-27, in Madrid, Spain.

How It Works, Simply

This oncology research focuses on . Researchers evaluated it using a phase III multicenter trial · Phase III clinical trial at the Phase III stage of medical research.

3 Key Takeaways

Clinical Takeaways
  1. 01Core Finding

    Delivered via first Cancer Vaccine, this Phase III approach targets .

  2. 02Study Evidence

    Tested in a Phase III multicenter trial · Phase III clinical trial at the Phase III stage.

  3. 03Practical Meaning

    Large Phase III clinical evidence — long-term durability and rare subgroup effects remain under study.

01

Biological Mechanism & Study Design

Study Design & Cohort

Phase III clinical trial

Phase III multicenter trial · Phase III clinical trial · Phase III

Biological Pathway & Modality

Intervention: First Cancer Vaccine

02

Experimental Findings & Endpoints

Adding the -based individualized vaccine intismeran autogene to the PD-1 inhibitor pembrolizumab following surgery for melanoma reduced the risk of disease recurrence or death substantially, according to the results of the Phase III INTerpath-0001 trial.

The data were presented at the ESMO Congress 2026, held October 23-27, in Madrid, Spain.

03

Clinical Translation & Practice Context

Published in Cancer discovery, these peer-reviewed oncology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.

03

The Bottom Line · Clinical Pearl

“The data were presented at the ESMO Congress 2026, held October 23-27, in Madrid, Spain.”

Published in Cancer Discovery · Current Stage: Phase III

Practical Next Step

Questions for Your Next Doctor Visit

  1. 1Based on my health history, do these oncology findings (phase III multicenter trial · Phase III clinical trial in oncology care) apply to my situation?
  2. 2How do the potential benefits of this approach compare with the standard care I'm currently using?
  3. 3Given the study's key limitation (large Phase III clinical evidence — long-term durability and rare subgroup effects remain under study.), what risks or follow-up steps should we watch for?
Oncology · Phase III
Study Type
Phase III clinical trial

Phase III multicenter trial · Phase III clinical trial

Evidence Score
5/5 · Gold-Standard Human Evidence
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

Who It Applies To
Phase III multicenter trial · Phase III clinical trial in oncology care
Intervention & Mechanism
First mRNA Cancer Vaccine

mRNA

Key Limitation
Large Phase III clinical evidence — long-term durability and rare subgroup effects remain under study.

Translational Stage

LEVEL 1 · Phase III

Classified as Phase III clinical trial along the clinical evidence continuum

  1. Lab & Discovery
  2. Early Trials
  3. 3Phase IIIActive
  4. 4Meta & Practice

Indexed Clinical Entities

mRNA Vaccines & TherapeuticsImmune Checkpoint Inhibitors

Original Publication & AMA Citation

First mRNA Cancer Vaccine Succeeds in Phase III Trial. Cancer Discovery. Published 2026;Oct 26. Accessed November 15, 2026. https://pubmed.ncbi.nlm.nih.gov/42929716/

Cancer Discovery

https://pubmed.ncbi.nlm.nih.gov/42929716/

Read Original Paper

Continue Reading

Related in Oncology

View all Oncology briefings →
ONCOLOGY · CLINICAL PRACTICE

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial

In this interim analysis, short-course radiotherapy followed by camrelizumab and CAPOX significantly improved 3-year event-free survival in patients with locally advanced rectal cancer, with a safety profile similar to long-course chemoradiotherapy followed by CAPOX. Comparison of this promising new treatment strategy with contemporary total neoadjuvant therapy strategies is warranted.

5/5 Gold Standard
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Oncology
ONCOLOGY · REAL-WORLD COHORT

Curative-intent management of de novo metastatic nasopharyngeal carcinoma: an evidence-based consensus guideline from the International Collaborating Oncology Organisations

This guideline provides a practical framework for standardisation of clinical management of de novo metastatic nasopharyngeal carcinoma and identification of key evidence gaps for future research. We recommend that curative-intent treatment should be offered to medically fit patients with no more than three metastatic lesions in two or fewer organs at baseline or following response to systemic therapy; multimodality treatment (comprising immunochemotherapy, locoregional radiotherapy, metastasis-directed therapy, and maintenance therapy) is recommended.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet Oncology
ONCOLOGY · REAL-WORLD COHORT

Development of the Children's Oncology Group long-term follow-up guideline for cancer genetics evaluation in childhood cancer survivors

Raising awareness of this guideline is crucial to enhancing the integration of genetics into survivorship care and improving health outcomes for childhood cancer survivors with CPS. This Policy Review details the importance, development, and anticipated impact of this new guideline.

3/5 Observational
Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readThe Lancet Oncology